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Background  and Objectives. Detection of PML-RARα
transcripts by RT-PCR is now established as a rapid and
sensitive method for diagnosis of acute promyelocytic
leukemia (APL). Although the majority of patients in long-
term clinical remission are negative by consecutive
reverse transcription polymerase chain reaction (RT-PCR)
assays, negative tests are still observed in patients who
ultimately relapse. Conversion from negative to positive
PCR has been observed after consolidation and found to
be a much stronger predictor of relapse. This study
reports on 47 APL patients to determine the correlation
between minimal residual disease (MRD) status and clin-
ical outcome in our cohort of patients.
Design and Methods. The presence of PML-RARα t tran-
scripts was investigated in 47 APL patients (37 adults
and 10 children) using a semi-nested reverse transcrip-
tase-polymerase chain reaction to evaluate the prognos-
tic value of RT-PCR tests. 
Results. All patients achieved complete clinical remis-
sion (CCR) following induction treatment with all-trans
retinoic acid (ATRA) and chemotherapy (CHT) or ATRA
alone. Patients were followed up between 2 and 117.6
months (median: 37 months). Relapses occurred in 11
patients (9 adults and 2 children) between 11.4 and 19
months after diagnosis (median: 15.1 months) while 36
patients (28 adults and 8 children) remained in CCR.
Seventy-ﬁve percent of patients carried the PML-RARα
long isoform (bcr 1/2) which also predominated among
the relapsed cases (9 of 11) but did not associate with
any adverse outcome (p= 0.37). For the purpose of this
analysis, minimal residual disease tests were clustered
into four time-intervals: 0-2 months, 3-5 months, 6-9
months and 10-24 months. 
Interpretation and Conclusions. Children showed per-
sisting disease for longer than adults during the ﬁrst 2
months of treatment.  At 2 months, 10 (50%) of 20
patients who remained in CCR and 4 (80%) of 5 patients
who subsequently relapsed were positive. Patients who
remained in CCR had repeatedly negative results beyond
5.5 months from diagnosis. A positive MRD test preced-
ed relapse in 3 of 4 tested patients. The ability of a neg-
ative test to predict CCR (predictive negative value, PNV)
was greater after 6 months (>83%), while the ability of
a positive test to predict relapse (predictive positive val-
ue, PPV) was most valuable only beyond 10 months
(100%). This study (i) highlights the prognostic value of
RT-PCR monitoring after treatment of APL patients but
only from the end of treatment, (ii) shows an association
between conversion to a positive test and relapse and (iii)
suggests that PCR assessments should be carried out at
3-month intervals to provide a more accurate prediction
of hematologic relapses but only after the end of treat-
ment.
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Key words: APL, RARα,  minimal residual disease
T
he PML-RARα fusion transcript is associated with
the t(15;17)(q21;q22) translocation and results from
the rearrangement of the PML gene on chromo-
some 15 and the RARα gene on chromosome 17.1-4 The
fusion product is transcriptionally active in all cases of
acute promyelocytic leukemia (APL) (M3 subtype in the
FAB classiﬁcation) whilst only 70% of the cases carry
the reciprocal RARα -PML.5-8 A breakpoint in intron 2 is
the common site on chromosome 17, while three dif-
ferent breakpoint regions have been described in the
PML gene on chromosome 15. This results in the gen-
eration of three different PML/RARα transcripts,
depending on whether the breakpoint in the PMLgene
affects intron 6 (bcr1; long type), exon 6 (bcr2; variant
type) or intron 3 (bcr3; short type).5,9
Ampliﬁcation of the PML-RARα transcripts by
reverse transcriptase polymerase chain reaction (RT-
PCR) is now established as a rapid and sensitive method
for diagnosing APL. This also enables identiﬁcation of
patients with the three different isoforms, and ﬁnally
provides a valuable method for the assessment of min-
imal residual disease (MRD) in these patients.5,10-15
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http://www.haematologica.it/2001_06/0577.htmRecent investigations have shown that the majority of
patients in long-term clinical remission have consecu-
tively negative RT-PCR tests. Nevertheless, clinical
relapses are often preceded by negative tests.16-18 The
short half-life of the PML-RARα mRNA and poor sen-
sitivity of the technique may be responsible for false
negative results. Despite the increased sensitivity of
recent assays,19 negative tests are still observed in
patients who ultimately relapse. More recently, con-
version from negative to positive PCR has been observed
after consolidation and found to be a much stronger
predictor of relapse.17 However, no consistency in the
time-interval between PCR conversion and time of
relapse was observed. Only larger studies or information
from more APL patients will improve the future inter-
pretation of MRD data and their signiﬁcance as prog-
nostic indicators of clinical outcome in APL. 
For this reason, we report here on a two-step RT-PCR
investigation of the PML-RARα transcript in 47 APL
patients . Although the patients studied were from dif-
ferent institutions, they were all treated with all trans
retinoic acid (ATRA) and chemotherapy (CHT). This study
aimed to determine the correlation between MRD sta-
tus and clinical outcome in our cohort of patients.
Design and Methods
Patients’ data
All 47 patients were diagnosed as having APL (AML-
M3) according to the FAB classiﬁcation.20 With the
exception of patient #5 (Figure 1) (who suffered sec-
ondary APL following treatment for breast cancer), all
cases had de novoAPL. Thirty-seven were adults (medi-
an age 37.8 years, range: 16-69; 21 were males and 16
females) and ten were children (median age: 7.0 years,
range: 1.5-14; 4 males and 6 females). Forty of the 47
patients were analyzed at time of referral using RT-
PCR: 33 were analyzed at presentation, 4 at 1 month
(cases #12, 21, 35, 43), 2 at 2 months (cases #31 and
46) and 1 at 10 months (case #39). In four other
patients (cases #2, 4, 6 and 24) the presence of the
t(15;17) was conﬁrmed by conventional cytogenetics.
In the 3 remaining cases (#1, 3 and 8) there was no
material available for molecular or cytogenetic analy-
sis at presentation and diagnosis was based on mor-
phologic and clinical evaluation. Following diagnosis, all
patients were monitored by RT-PCR for an average of
19.3 months (range: 1.1 to 97.9 months). Patients
received different therapeutic protocols but all includ-
ed ATRA during the induction period. The number of
consolidation cycles varied between 1 and 4. Eleven
patients (10 children and 1 adult) received maintenance
treatment.  Five patients (#7, 9, 28, 38 and 43) have
been previously reported (Devaraj et al., 1996).
Samples and RNA preparation
The number of tests performed varied between 1 and
9 tests per patient (average 4 tests). Bone marrow (BM)
(n=184) and peripheral blood (PB) (n=5) samples were
used for follow-up investigations. The mononuclear cells
were isolated by density gradient centrifugation in Ficoll-
Hypaque (Nycomed Pharma AS, Oslo, Norway) and
washed twice in phosphate-buffered saline (PBS). Cells
were lysed in 4M guanidium thiocyanate (GITC) solution
and stored at -70°C. Total RNA was extracted by the
method of Chomczynsky and Sacchi.21 In 14 patients
RNA was prepared using the Gentra extraction kit (Gen-
tra, UK). Four time periods were analyzed: 0-2 months,
3-5 months, 6-9 months and 10-24 months. The result
of the last sample tested was used for MRD analysis in
patients with more than 1 test in each time period.
RT-PCR
The protocol and the primers used to amplify the
PML-RARα fusion transcript were adapted from a pre-
viously described protocol.5 Brieﬂy, 1 µ g of total RNA
was reverse transcribed (RT) into cDNA in a 20 µ L reac-
tion for 90 min at 37°C using random hexamers
(Promega, Madison, WI, USA), 40 U of RNAse inhibitor
(Promega), 1 mM dNTP (Pharmacia Biotech, USA) and
200 U of Superscript II RNAse H Reverse Transcriptase
(Gibco BRL, Bethesda Research, Gaithersburg, MD, USA)
according to the manufacturers’ instructions.  Two and
a half microliters of cDNA were ﬁrst ampliﬁed in a 50
µ L reaction using the oligonucleotides M4-M5 or M2-
M55with 2.5 U of Taq DNA polymerase (Gibco, BRL), 1.5
mM MgCl2, 200 mM dNTPs and 15 pM of each primer.
PCR was carried out in a DNA thermal cycler machine
(Perkin Elmer-Cetus) for 35 cycles (50 sec at 94°C, 50
sec at 59°C and 90 sec at 72°C). One microliter of the
ﬁrst round ampliﬁcation was re-ampliﬁed in a semi-
nested reaction for another 35 cycles, using primers
M4-R8 or M2-R8,5under the same conditions as for the
ﬁrst round ampliﬁcation. The PCR products were ana-
lyzed on a 1.5% agarose gel and visualized by ethidi-
um bromide staining. To evaluate the integrity of the
RNA and assess the efﬁciency of the RT step, each sam-
ple was also ampliﬁed using primers for the RARα tran-
script under the same conditions as for the PML-RARα
transcripts.  A positive control (total RNA extracted from
the promyelocytic cell line NB4) and a negative control
(no RNA) were included in each experiment. 
Sensitivity tests
To assess the sensitivity of the RT-PCR, serial dilutions
of RNA from an APL patient and from the NB4 cell line
were set up using RNA from the HL60 cell line. All pro-
cedures were done using RNAse free disposable mate-
rial. Both the bcr1 (long form) and the bcr3 (short form)
transcripts were obtained from the control ampliﬁca-
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 tion tests using 0.1 ng of total positive RNA (i.e. sensi-
tivity of 1:1× 104).
Statistical analysis
Standard statistical tests were carried out (Fisher’s
exact test, χ 2 contingency tests, and parametric and
non-parametric t-tests) using the statistic programs
GraphPad Prism, and SPSS. Disease-free survival (DFS)
curves were generated using the Kaplan-Meier
method,22 and compared with the logrank test. The
impact of multiple predictor variables on DFS was




Thirty-six patients (28 adults and 8 children) remained
in CCR between 2 and 117.6 months (Figure 1) from
when they were ﬁrst referred (median period: 43.7
months). The median period of DFS in this group was
41.7 months (range 1-114.7 months).  Eleven patients (9
adults and 2 children) relapsed between 11.4 and 19
months (median 15.1) after presentation (Figure 2), fol-
lowing CCR for a median period of 13.3 months (range
10-16.5). The clinical and biological characteristics of
patients at the time of diagnosis are presented in Table
1. Age appeared to have no impact on overall clinical
outcome (p= 1.0, Fisher’s exact test). All patients had
achieved CCR following induction treatment with ATRA
and chemotherapy or ATRA alone (median time: 54 days;
range 28-102 days; 56 days in adults and 50 in children).
Patients who later relapsed achieved ﬁrst CCR between
35 and 90 days (median 57 days; adults 56 and children
58 days) which was comparable with the time in
patients who remained in remission (range 28 and 102
days; median 53 days; adults 55 and children 48
days)(p=0.32, Mann-Whitney t-test). 
The induction therapy using ATRA or ATRA plus
chemotherapy did not result in better overall survival
(Figure 3A) (p=0.94, logrank test) as we observed relaps-
es in 4 (24%) of 17 patients in the ATRA group and in
7 (23%) of 30 cases in the ATRA plus chemotherapy
group. Patients who received 3 or 4 cycles of
chemotherapy following induction did not appear to
have a better overall survival compared to the group
who received 1 or 2 chemotherapy cycles as we
observed relapses in 11% and 33% of patients in these
two groups, respectively (p=0.07, logrank test; Figure
3B) although a trend towards a better outcome was
associated with the higher number of cycles. 
PML/RARαα isoforms
The PML/RARα isoforms (bcr1/2 and bc3) were iden-
tiﬁed by RT-PCR in 40 patients. Thirty-three patients
were analyzed at presentation, 4 at 1 month, 2 at 2
months and 1 patient (case #39) at 10 months, in CCR.
The bcr1/2 (long form) was detected in 30 (75%)
patients, 21 of them remained in CCR and 9 relapsed.
The bcr3 (short form) was detected in 10 (25%) patients,
8 remained in CCR and 2 relapsed. There was no differ-
ence in the distribution of the isoforms between the
two age groups (p=1.00, Fisher’s exact test). Although
9 of 11 patients who relapsed carried the bcr1/2 form,
there was no statistically signiﬁcant difference in the
incidence of the PML/RARα isoform types between the
relapsed and CCR group (p=0.69, Fisher’s exact) and nei-
ther isoform conferred better or worse disease-free sur-
vival (p=0.72, logrank test; Figure 3C). 
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A) ADULTS Months from presentation
PT  BCR Induction Consolid.Mainten.0 1  2 3 4 5 6789 1 0 1 1 1 2 post 13
37 bcr1/2 atra+cht 2x no     rd     rd R (19.0 mo)
38 bcr3 atra  3x and BMT no     rd A R (17.9 mo)
39 bcr1/2 atra+cht 1x no R (15.9 mo)
40 bcr1/2 atra 1x no R (15.9 mo)
41 bcr3 atra+cht 1x no R (14.4 mo)
42 bcr1/2 atra 1x no R (14.3 mo)
43 bcr1/2 atra 4x  no     rd R (13.1 mo)
44 bcr1/2 atra+cht 2x no rd R (12.0 mo)
45 bcr1/2 atra+cht 1x no R (11.4 mo)
B) CHILDREN
46 bcr1/2 atra+cht 2x yes R (16.2 mo)
47 bcr1/2 atra+cht 2x yes     rd R (16.0 mo)
Figure  2. RT-PCR ampliﬁcation of PML-RARαα transcript during follow-up of 11 APL patients who relapsed. Symbols and abbre-
viations are as in Figure 1. R: relapse time (in months) from presentation.PML-RARα transcript in lomg-term follow-up of APL 581











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The results of MRD analysis of 189 samples are illus-
trated in Figure 1 for patients remaining in CCR (A:
adults; B: children) and in Figure 2 for relapsed patients
(A: adults; B: children). At 1 month all patients tested
were RT-PCR positive (including 14/17 patients who
had resistant disease, RD), irrespective of age and clin-
ical outcome. At 2 months, 50% (10 of 20) of the
patients tested in the CCR group were negative, while
only 1 of the 5 patients in the relapsed group was RT-
PCR negative. Tests carried out between 3-5 and 6-9
months were almost all negative (with the exception of
4 patients with a positive result who remained in CCR),
including in 10 of the 11 patients who later relapsed.  
We observed a rapid decrease in the level of disease
during the ﬁrst 2 months of monitoring, with the adults
showing a more rapid molecular clearance of disease
than the children: 83% (5 of 6) of the children were still
positive against 41.2% (7 of 17) of the adults.  Howev-
er, the slower reduction in MRD cases at 2 months did
not result in a higher incidence of relapses in the
younger age group: 2 (20%) of 10 children versus 9
(24.3%) of 37 adults (p=1.0, Fisher’s exact test). CCR
patients had serially negative RT-PCR results beyond
5.5 months. However, 4 patients (3 adults and 1 child)
who later relapsed also had negative results at 6-9
months. Moreover, only negative tests were recorded 4,
7, 8, 10, 11, 11, 12 and 13 months prior to relapse in 8
patients (Figure 2A-B). Residual disease beyond 10
months was observed in 3 of 4 adults who relapsed 2,
5 and 7 months after the positive RT-PCR (#45, 37 and
39, respectively). 
Statistical analysis of MRD tests
The ability of a positive test to predict relapse (pre-
dictive positive value, PPV) was better (100%) between
10-24 months than in any previous time-interval. The
ability of a negative test to predict CCR (predictive neg-
ative value, PNV) was also highest at 10-24 months
with 17 (94%) of 18 MRD negative tests among
patients who remained in CCR.  During treatment a
negative test was invariably better at predicting CCR,
(PNV: 91%, 76% and 83% at 0-2 months, 3-5 months
and 6-9 months, respectively), than a positive test at
predicting relapse (PPV: 20%, 0% and 0% at 0-2
months, 3-5 months and 6-9 months, respectively). 
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Figure  3. Survival curves (Kaplan Meier method). A) DFS and induction therapy: ATRA alone versus ATRA plus chemotherapy
(CHT), B) DFS and consolidation therapy: 1 or 2 cycles of chemotherapy versus 3 or 4 cycles, C) Disease-free-survival (DFS)
and PML/RARαα    isoforms: bcr1/2 versus bcr3 forms (n= number of patients), D) DFS and MRD tests obtained 10-24 months
after presentation: RT-PCR positive versus RT-PCR negative results. The correlation between MRD tests and disease-free
survival (DFS) was investigated in each of the four time-
intervals: 0-2 months, 3-5 months, 6-9 months,10-24
months with only tests at 10-24 months reaching sta-
tistical signiﬁcance (p<0.0001, logrank test) (Figure 3D).
A Cox-regression multi-variant model was used to
determine the variable that was most signiﬁcantly
prognostic of the DFS rate. MRD-status at each time
period was compared with sex, age and days to CR
(Table 2). The only co-variable to have a signiﬁcant
independent impact on the DFS was the MRD status at
the 10-24 month mesasurement period: p=0.016 (the
Wald statistics was also its highest and the Exp(B) devi-
ated most from the numerical one).
Discussion
Treatment with ATRA and chemotherapy has dra-
matically improved survival in APL patients18,19,24,25 and
RT-PCR studies (using the PML-RARα fusion tran-
scripts) have been extensively used to monitor the efﬁ-
cacy of these therapeutic regimens. The patients in our
study came from different institutions which used dif-
ferent therapeutic strategies but these all included
ATRA and one or more cycles of chemotherapy, with a
trend towards a better overall outcome for patients
who received more than two cycles of chemotherapy,
following induction therapy, although this did not reach
statistical signiﬁcance (p=0.07). 
The bcr3 transcript (short isoform) has been associat-
ed in different studies with adverse prognosis but no sta-
tistically signiﬁcant correlation has been established with
clinical outcome.19,25 In our study relapse was observed
mainly in patients carrying the bcr1/2 (long isoform)
while the majority of the patients carrying the bcr3 tran-
script remained in CCR. We observed no difference in
overall incidence and outcome between patients carry-
ing either isoform in the two age groups analyzed. 
In other studies, long-term survivors have been asso-
ciated with the ﬁnding of persistently negative MRD
results11,13,15,25-27suggesting eradication of the malignant
clone, at least below the level of sensitivity of the RT-PCR
test. In our series, all patients who have remained in CCR
were serially RT-PCR negative from 5.5 months onwards
irrespective of age (Figure 1A-B) with the PNV greatly
improving beyond 5 months. However, 10 patients who
later relapsed also converted to negative MRD after
achieving clinical remission and tested negative at the
end of therapy (time-period 6-9 months) (Figure 2A-B).
This is suggestive of a poor ability of the MRD tests to
detect future relapse or a rapid rise of residual disease
pre-relapse (see below). 
Our data indicate that during the ﬁrst 9 months, the
ability of a negative test to predict CCR is stronger than
the ability of a positive test to predict relapse. Howev-
er, with only negative tests detected among patients
who later relapsed, our MRD study shows that there is
little advantage in assessing patients during treatment
and greater effort should be made to monitor disease
beyond the end of treatment, as this is the best time to
pick up patients destined to relapse (p<0.0001).  
Overall there was little difference in MRD results
between the two age groups. The persistence of resid-
ual disease during the ﬁrst 2 months of treatment was
longer in children than in adults but did not translate
into a worse outcome in the younger age group. This
was rather unexpected as children with acute leukemia
of B-cell origin have a more rapid clearance of disease
than adults, as previously suggested.28 We did not
observe a higher incidence of the bcr3 isoform in
younger patients or a different clinical outcome for the
patients with this isoform. 
Our MRD investigation results expand data from our
own previous study16and conﬁrm data from other inves-
tigators18 both in highlighting the poor ability of early
tests to predict outcome and in describing the limited
ability of MRD tests during treatment to predict overall
outcome. Either inefﬁciency of the RT steps or low lev-
els of PML-RARα expression29 might explain the high
rate of negative tests. However, the high level of posi-
tive tests during the 0-2 months period is a strong argu-
ment, in our view, against technical reasons being the
cause. Also, more sensitive (1:106) competitive RT-PCR
tests can detect MRD in patients in CCR who tested
negative using a less sensitive conventional RT-PCR
(1:1× 104).30 However, a more important biological fea-
ture could also explain this apparent poor performance
of the tests. The rate at which cells are cleared follow-
ing therapy is slower than the rate at which leukemic
cells divide and re-appear preceding relapse. This has
been demonstrated in studies of patients with Philadel-
phia chromosome positive acute lymphoblastic leukemia
following bone marrow transplantation.31 Very low or
even undetectable levels of MRD preceded relapse in
this group of patients. This is not the case, for instance,
for patients with chronic myeloid leukemia who show
PML-RARα transcript in lomg-term follow-up of APL 583
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Table 2. Cox-regression model analysis of effects on dis-
ease-free-survival of four co-variants: MRD-status, age, sex
and days to CCR.
Co-variables Cases Wald  Statistic Exp(B) p-value
10-24 months (21)
MRD status 5.848 181.229 0.016
Days to 1st CR 1.929 0.925 0.165
Sex 0.306 3.504 0.580
Age 0.031 0.989 0.859persistence of MRD for very long periods. In these
patients the rate at which the BCR-ABL transcripts dis-
appear is relevant in predicting outcome. Those who are
slow to achieve a remission are more likely to relapse
than those who reach this state quickly.32 The kinetics
of cells becoming undetectable is inﬂuenced more by
the disease-type than by the technique applied.
The positive results observed during the monitoring
of three of the relapsed patients are also in accord with
those of previous studies which described the reap-
pearance of the leukemic clone prior to relapse.11,15,17,18,27
However, in 8 of our patients, no prior PCR conversion
was observed, although, no bone marrow sample was
tested within the 6 to 9 months preceding relapse in 7
of these 8 patients. This strongly argues for a policy of
monitoring MRD at 3-monthly intervals in the bone
marrow of APL patients in any future study in order to
avoid false negative tests after the end of treatment. 
In conclusion, our study highlights the poor predic-
tive value of MRD during treatment in APL patients and
the requirement for regular (3-monthly) sampling for
MRD investigation, after the end of treatment. In a
small cohort of patients we have conﬁrmed the value
of the RT-PCR positive conversion in predicting relapse.
There is great expectation that the advent of real-time
RT-PCR technology will in the future allow for more
accurate and rapid monitoring of residual disease in
APL patients. Preliminary results have shown that this
technology is suitable for assessing the rate of clearance
of PML-RARα transcripts and that its sensitivity can be
superior to that of the conventional RT-PCR.33,34 It is
likely that the application of this technique to large
prospective trials will improve the identiﬁcation of APL
patients at risk of relapse. 
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Potential implications for clinical practice
Our results have a primary implication for the man-
agement and stratiﬁcation of APL patients36-39 accord-
ing to MRD which is already being applied to a large
cohort of patients in Europe and the USA.
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